Full Press Release Details
DUBLIN , Oct. 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT to discuss third quarter 2017 financial results and provide a business and financial update.
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call: U.S. Dial-In Number: +1 855 353 7924 International Dial-In Number: +1 503 343 6056 Passcode: 95499424
A replay of the conference call will be available through November 14, 2017 and accessible through one of the following telephone numbers, using the passcode below:
Replay U.S. Dial-In Number: +1 855 859 2056 Replay International Dial-In Number: +1 404 537 3406 Passcode: 95499424
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi ), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com .
SOURCE Jazz Pharmaceuticals plc